S&P Futures
4,139.00 +8.50 (+0.21%) Dow Futures
34,078.00 +83.00 (+0.24%) Nasdaq Futures
12,577.75 +32.50 (+0.26%) Russell 2000 Futures
1,954.60 +4.70 (+0.24%) Crude Oil
78.40 -0.07 (-0.09%) Gold
1,891.10 +0.40 (+0.02%)
Akari Therapeutics, Plc (AKTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.4688 |
| Open | 0.4775 |
| Bid | 0.4601 x 1400 |
| Ask | 0.5000 x 1000 |
| Day's Range | 0.4550 - 0.4775 |
| 52 Week Range | 0.3800 - 1.6100 |
| Volume | |
| Avg. Volume | 76,135 |
| Market Cap | 34.79M |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5410 |
| Earnings Date | Dec 07, 2022 - Dec 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Akari Therapeutics to Present at Biotech Showcase™ 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a nove
- GlobeNewswire
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022. Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 a
- GlobeNewswire
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Ophthalmology Day at BTIG on November 29, 2022. President and CEO Rachelle Jacques will participate in a fireside chat scheduled for 9:30 am ET. Akari will be discussing progress in the development of long-acting PAS-nomacopan in geographic
